Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

0.65USD
2:29am IST
Change (% chg)

$0.00 (+0.05%)
Prev Close
$0.65
Open
$0.66
Day's High
$0.67
Day's Low
$0.63
Volume
108,539
Avg. Vol
150,030
52-wk High
$2.36
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Q3 Loss Per Share $0.08
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q3 LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S.AT QUARTER END, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $43.2 MILLION, VERSUS $49.9 MILLION AS OF JUNE 30, 2018.  Full Article

Catabasis Pharmaceuticals Inc - Collaboration with university of Texas Southwestern
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC - COLLABORATION WITH UNIVERSITY OF TEXAS SOUTHWESTERN.CATABASIS PHARMACEUTICALS -COLLABORATION TO EXPLORE POTENTIAL BENEFITS OF EDASALONEXENT ON CARDIAC FUNCTION IN DUCHENNE , BECKER MUSCULAR DYSTROPHIES.CATABASIS PHARMACEUTICALS INC - RESULTS ARE EXPECTED IN SECOND HALF OF 2019.  Full Article

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.20
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.20.Q2 EARNINGS PER SHARE VIEW $-0.23 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, HAD CASH, CASH EQUIVALENTS OF $49.9 MILLION, COMPARED TO $17.0 MILLION AS OF MARCH 31, 2018.BASED ON CO'S CURRENT OPERATING PLAN, BELIEVES IT HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2020.  Full Article

Catabasis Pharmaceuticals Presents New Edasalonexent Data
Thursday, 26 Apr 2018 

April 25 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT.CATABASIS PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MRI T2 RATE OF CHANGE.  Full Article

Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent
Wednesday, 18 Apr 2018 

April 17 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION.CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANY'S WORKFORCE BY APPROXIMATELY 42%.CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS.CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018.  Full Article

Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22
Thursday, 5 Apr 2018 

April 4 (Reuters) - Catabasis Pharmaceuticals Inc ::CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC <<>> AS OF MARCH 22 - SEC FILING .CLARUS LIFESCIENCES II LP PREVIOUSLY REPORTED A 11.92 PERCENT STAKE IN CATABASIS PHARMACEUTICALS AS OF OCT. 31, 2017.  Full Article

Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24
Friday, 16 Mar 2018 

March 15 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.24.Q4 REVENUE $300,000.Q4 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.CATABASIS PHARMACEUTICALS - PLANS TO INITIATE A GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN H1 2018.  Full Article

Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT.CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018.CATABASIS PHARMACEUTICALS - ‍EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL​.CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020.  Full Article

Catabasis Pharmaceuticals reports third quarter financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress.Q3 loss per share $0.31.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - co's current operating plan provides for cash to fund operations through august 2018​.  Full Article

Catabasis Pharmaceuticals reports positive DMD drug data
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc ::Catabasis Pharmaceuticals reports positive results from open-­label extension of phase 2 MoveDMD trial evaluating edasalonexent in duchenne muscular dystrophy.Catabasis Pharmaceuticals says edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks in phase 2 trial.Plans to initiate single global phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in first half of 2018.Catabasis Pharmaceuticals says top-­line results from single global phase 3 trial with edasalonexent expected in 2020.Catabasis Pharmaceuticals says edasalonexent continued to be well tolerated with no safety signals observed to date in movedmd trial.  Full Article